OBN (UK) Ltd
OBN is the not-for-profit Membership organisation supporting and bringing together the UK’s life sciences companies, corporate partners and investors. Our 400-plus Member companies are located across the Golden Triangle and beyond to Manchester, Nottingham, the Midlands, South Coast and Scotland, benefiting from our networking, partnering, purchasing, training, advising and advocacy activities.
OFX is a global company that provides international money transfers at competitive exchange rates for both businesses and consumers. It offers fee-free transactions, 24/7 customer service and rapid round-the-clock transfers thanks to its unique ‘follow-the-sun’ service model.
Oncimmune’s intimate understanding of the human immune system enables the Company to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies.
The key to improving cancer survival is early detection and optimal selection for therapy. Oncimmune is driven by a passion to improve cancer survival and to give people extra time. Oncimmune's immuno-diagnostic test, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis.
The unique combination of our core technology and understanding of the immune system, powers our ImmunoINSIGHTS service; a proprietary platform that enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted as well as safer treatments for patients.
Oncimmune was founded in 2002 and launched its platform diagnostic technology in 2009, followed by the launch of its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 200,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled trial for the early detection of lung cancer using biomarkers, the successful NHS Early detection of Cancer of the Lung (ECLS) trial of 12,209 high-risk smokers in Scotland. This trial demonstrated that EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.
Headquartered at its laboratory facility in Nottingham, UK, Oncimmune has a discovery research centre in Dortmund, Germany and in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.
One Nucleus is a Cambridge/London Life Science membership organisation. We support Europe’s largest Life Science cluster encompassing the London-Cambridge-East of England region via knowledge transfer, connectivity, inward investment and growth.
Oppilotech develops first-in-class drugs. We believe that target selection is the most important decision we make in drug discovery – a selective high-quality molecule will never become a drug if it is modulating the wrong target. Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets. We undertake both the target selection and develop the drugs against the identified target. We initially focused our modelling efforts on E.coli identifying several first-in-class antibacterial drug targets and generated active chemical matter against them. The company intends to develop these programmes towards the clinic. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (e.g. DNA Damage Response) and inflammation.
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people.